{"title":"抗逆转录病毒药物比特拉韦对大鼠外周血单核细胞中与 P-gp、Bcrp 和 Mrp1 转运体相关的 Abcb1、Abcg2 和 Abcc1 基因表达的诱导作用。","authors":"Tarang Jadav, Niraj Rajput, Hemant Kumar, Santosh Kumar Behera, Pinaki Sengupta","doi":"10.1080/17425255.2024.2352462","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antiretrovirals have the potential to cause drug interactions leading to inefficacy or toxicity via induction of efflux transporters through nuclear receptors, altering drug concentrations at their target sites.</p><p><strong>Research design and methods: </strong>This study used molecular dynamic simulations and qRT-PCR to investigate bictegravir's interactions with nuclear receptors PXR and CAR, and its effects on efflux transporters (P-gp, BCRP, MRP1) in rat PBMCs. PBMC/plasma drug concentrations were measured using LC-MS/MS to assess the functional impact of transporter expression.</p><p><strong>Results: </strong>Bictegravir significantly increased the expression of ABC transporters, with Car identified as a key mediator. This suggests that bictegravir's influence on nuclear receptors could affect drug transport and efficacy at the cellular level.</p><p><strong>Conclusions: </strong>Bictegravir activates nuclear receptors enhancing efflux transporter expression. Understanding these interactions is crucial for preventing drug-drug interactions and reducing toxicity in clinical use. Combining CAR antagonists with bictegravir may prevent drug resistance and toxicity. However, these findings are based on preclinical data and necessitate further clinical trials to confirm their applicability in clinical settings.</p>","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"529-539"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Induction effect of antiretroviral bictegravir on the expression of Abcb1, Abcg2 and Abcc1 genes associated with P-gp, BCRP and MRP1 transporters present in rat peripheral blood mononuclear cells.\",\"authors\":\"Tarang Jadav, Niraj Rajput, Hemant Kumar, Santosh Kumar Behera, Pinaki Sengupta\",\"doi\":\"10.1080/17425255.2024.2352462\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Antiretrovirals have the potential to cause drug interactions leading to inefficacy or toxicity via induction of efflux transporters through nuclear receptors, altering drug concentrations at their target sites.</p><p><strong>Research design and methods: </strong>This study used molecular dynamic simulations and qRT-PCR to investigate bictegravir's interactions with nuclear receptors PXR and CAR, and its effects on efflux transporters (P-gp, BCRP, MRP1) in rat PBMCs. PBMC/plasma drug concentrations were measured using LC-MS/MS to assess the functional impact of transporter expression.</p><p><strong>Results: </strong>Bictegravir significantly increased the expression of ABC transporters, with Car identified as a key mediator. This suggests that bictegravir's influence on nuclear receptors could affect drug transport and efficacy at the cellular level.</p><p><strong>Conclusions: </strong>Bictegravir activates nuclear receptors enhancing efflux transporter expression. Understanding these interactions is crucial for preventing drug-drug interactions and reducing toxicity in clinical use. Combining CAR antagonists with bictegravir may prevent drug resistance and toxicity. However, these findings are based on preclinical data and necessitate further clinical trials to confirm their applicability in clinical settings.</p>\",\"PeriodicalId\":94005,\"journal\":{\"name\":\"Expert opinion on drug metabolism & toxicology\",\"volume\":\" \",\"pages\":\"529-539\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert opinion on drug metabolism & toxicology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17425255.2024.2352462\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on drug metabolism & toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17425255.2024.2352462","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/13 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:抗逆转录病毒药物有可能通过核受体激活外排转运体,改变靶点的药物浓度,从而引起药物相互作用,导致药物无效或中毒:本研究采用分子动力学模拟和qRT-PCR技术研究比特拉韦与大鼠PBMCs中核受体Pxr和Car的相互作用及其对药物外排转运体(P-gp、Bcrp、Mrp1)的影响。使用LC-MS/MS测定大鼠PBMC/血浆药物浓度,以评估转运体表达的功能影响:结果:比特拉韦能明显增加 ABC 转运体的表达,而 Car 被认为是其中的关键介质。这表明比特拉韦对核受体的影响可能会影响药物在细胞水平的转运和疗效:结论:比特拉韦可激活核受体,增强外流转运表达。结论:比特拉韦可激活核受体,增强外排转运表达,了解这些相互作用对于防止药物间相互作用和减少临床应用中的毒性至关重要。将 Car 拮抗剂与比特拉韦联合使用可防止耐药性和毒性。然而,这些发现都是基于临床前数据,还需要进一步的临床试验来证实它们在临床环境中的适用性。
Induction effect of antiretroviral bictegravir on the expression of Abcb1, Abcg2 and Abcc1 genes associated with P-gp, BCRP and MRP1 transporters present in rat peripheral blood mononuclear cells.
Background: Antiretrovirals have the potential to cause drug interactions leading to inefficacy or toxicity via induction of efflux transporters through nuclear receptors, altering drug concentrations at their target sites.
Research design and methods: This study used molecular dynamic simulations and qRT-PCR to investigate bictegravir's interactions with nuclear receptors PXR and CAR, and its effects on efflux transporters (P-gp, BCRP, MRP1) in rat PBMCs. PBMC/plasma drug concentrations were measured using LC-MS/MS to assess the functional impact of transporter expression.
Results: Bictegravir significantly increased the expression of ABC transporters, with Car identified as a key mediator. This suggests that bictegravir's influence on nuclear receptors could affect drug transport and efficacy at the cellular level.
Conclusions: Bictegravir activates nuclear receptors enhancing efflux transporter expression. Understanding these interactions is crucial for preventing drug-drug interactions and reducing toxicity in clinical use. Combining CAR antagonists with bictegravir may prevent drug resistance and toxicity. However, these findings are based on preclinical data and necessitate further clinical trials to confirm their applicability in clinical settings.